Drugs / Entelon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05358080 | May 2022 → Dec 2024 | diabetic retinopathy | Hanlim Pharm. Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Entelon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05358080 ↗ |